Patent application number | Description | Published |
20090215710 | CARBOHYDRATE BASED TOLL-LIKE RECEPTOR (TLR) ANTAGONISTS - The invention provides carbohydrate based compounds, methods of preparation, and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a carbohydrate based compound of the invention having a core structure comprising of one or more sugar moieties. The carbohydrate based compounds are useful for inhibiting immune stimulation involving TLR ligands, especially TLR4 and TLR2. The compounds also are suitable for inhibition of inflammatory conditions resulting from infections. The compounds have use in the treatment of inflammation, autoimmunity, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency. | 08-27-2009 |
20090215908 | TOLL LIKE RECEPTOR (TLR) SIGNALING ANTAGONIST - The present invention relates to novel synthetic toll like receptor antagonist. The present invention in particular provides compounds, methods and compositions for specifically inhibiting immune stimulation involving TLR ligands, especially TLR-4. The compounds are potentially useful in treatment of inflammation, autoimmunity, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency. | 08-27-2009 |
Patent application number | Description | Published |
20130295614 | NUCLEOTIDE SEQUENCES, METHODS, KIT AND A RECOMBINANT CELL THEREOF - The present disclosure relates to recombinant adeno-associated virus (AAV) vector serotype, wherein the capsid protein of AAV serotypes is mutated at single or multiple sites. The disclosure further relates to an improved transduction efficiency of these mutant AAV serotypes. The AAV serotypes disclosed are AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10. The instant disclosure relates to nucleotide sequences, recombinant vector, methods and kit thereof. | 11-07-2013 |
20140162319 | NUCLEOTIDE SEQUENCES, METHODS, KIT AND A RECOMBINANT CELL THEREOF - The present disclosure relates to recombinant adeno-associated virus (AAV) vector serotype, wherein the capsid protein of AAV serotypes is mutated at single or multiple sites. The disclosure further relates to an improved transduction efficiency of these mutant AAV serotypes. The AAV serotypes disclosed are AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10. The instant disclosure relates to nucleotide sequences, recombinant vector, methods and kit thereof. | 06-12-2014 |